Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Madan Website

Ravi A. Madan, M.D.

Selected Publications

1)  Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Oncologist. 18: 821-2, 2013.
2)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 62: 1521-31, 2013.
3)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. [Epub ahead of print], 2013.
4)  Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Clin Genitourin Cancer. 11: 229-37, 2013.
5)  Madan RA, Gulley JL.
Prostate cancer: Intermediate efficacy end points to assess modern therapies.
Nat Rev Urol. 10: 686-7, 2013.
6)  Madan RA, Arlen PM.
Recent advances revolutionize treatment of metastatic prostate cancer.
Future Oncol. 9: 1133-44, 2013.
7)  Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
J. Immunol. 190: 6250-8, 2013.
8)  Gulley JL, Madan RA, Heery CR.
Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer.
Am Soc Clin Oncol Educ Book. 166-70, 2013.
9)  Kim JW, Bilusic M, Heery CJ, Madan RA.
Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.
Cancers (Basel). 4: 1229-46, 2012.
10)  Madan RA, Gulley JL, Kantoff PW.
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
Cancer J. 19: 50-8, 2013.
11)  Singh N, Madan RA, Gulley JL.
Ipilimumab in prostate cancer.
Expert Opin Biol Ther. 13: 303-13, 2013.
12)  Madan RA, Shah AA, Dahut WL.
Is It Time to Reevaluate Definitive Therapy in Prostate Cancer?.
J. Natl. Cancer Inst. [Epub ahead of print], 2013.
13)  Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
BJU Int. [Epub ahead of print], 2013.
14)  Huen N, Pang AL, Tucker JA, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY.
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
Int. J. Cancer. [Epub ahead of print], 2013.
15)  Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines.
Semin. Oncol. 39: 296-304, 2012.
16)  Madan RA, Heery CR, Gulley JL.
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
Oncoimmunology. 1: 1167-1168, 2012.
17)  Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J.
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
Blood. 120: 3030-8, 2012.
18)  Kim JW, Madan RA, Gulley JL.
Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine.
Clin Genitourin Cancer. 10: 43-6, 2012.
19)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
20)  Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL.
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis. 15: 289-95, 2012.
21)  Madan RA, Schwaab T, Gulley JL.
Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
J Natl Compr Canc Netw. 10: 1505-12, 2012.
22)  Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL.
The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology.
J. Nucl. Med. 53: 1175-84, 2012.
23)  Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Eur. Urol. 61: 639-47, 2012.
24)  Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D.
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
Expert Opin Biol Ther. 11: 1409-18, 2011.
25)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
26)  Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY.
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Cancer Immunol. Immunother. 60: 197-206, 2011.
27)  Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.
From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer.
Expert Rev Vaccines. 10: 743-53, 2011.
28)  Bilusic M, Heery C, Madan RA.
Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
Vaccine. 29: 6485-97, 2011.
29)  Gulley JL, Madan RA, Schlom J.
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
Curr Oncol. 18: e150-7, 2011.
30)  Madan RA, Pal SK, Sartor O, Dahut WL.
Overcoming chemotherapy resistance in prostate cancer.
Clin. Cancer Res. 17: 3892-902, 2011.
31)  Madan RA, Gulley JL.
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.
Expert Rev Vaccines. 10: 141-50, 2011.
32)  Madan RA, Gulley JL.
Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.
Immunotherapy. 3: 27-31, 2011.
33)  Bilusic M, Madan RA.
Therapeutic Cancer Vaccines: The Latest Advancement in Targeted Therapy.
Am J Ther. 19: e172-81, 2011.
34)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
35)  Aragon-Ching JB, Madan RA, Dahut WL.
Angiogenesis inhibition in prostate cancer: current uses and future promises.
J Oncol. 2010: 361836, 2010.
36)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
37)  Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 2070-6, 2010.
38)  Dahut WL, Madan RA.
Revisiting the ultimate target of treatment for prostate cancer.
Lancet. 375: 1409-10, 2010.
39)  Madan RA, Gulley JL.
The current and emerging role of immunotherapy in prostate cancer.
Clin Genitourin Cancer. 8: 10-6, 2010.
40)  Madan RA, Gulley JL, Fojo T, Dahut WL.
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.
Oncologist. 15: 969-75, 2010.
41)  Madan RA, Mohebtash M, Schlom J, Gulley JL.
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.
Expert Opin Biol Ther. 10: 19-28, 2010.
42)  Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW.
Vaccines as monotherapy and in combination therapy for prostate cancer.
Clin Transl Sci. 3: 116-22, 2010.
43)  Madan RA, Dahut WL.
Angiogenesis inhibition in the treatment of prostate cancer.
Anticancer Agents Med Chem. 9: 1070-8, 2009.
44)  Mohebtash M, Gulley JL, Madan RA, Ferrara T, Arlen PM.
Cancer vaccines: current directions and perspectives in prostate cancer.
Curr. Opin. Mol. Ther. 11: 31-6, 2009.
45)  Kamrava M, Tsang KY, Madan RA, Kaushal A, Coleman CN, Gulley J.
Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.
Clin. Dev. Immunol. 2009: 363914, 2009.
46)  Arlen PM, Mohebtash M, Madan RA, Gulley JL.
Promising novel immunotherapies and combinations for prostate cancer.
Future Oncol. 5: 187-96, 2009.
47)  Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL.
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.
Expert Opin Investig Drugs. 18: 1001-11, 2009.
48)  Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL.
Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
Am J Ther. 17: 176-81, 2009.
49)  Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clin. Cancer Res. 14: 4526-31, 2008.
50)  Mohebtash M, Madan RA, Gulley JL, Arlen PM.
Therapeutic prostate cancer vaccines: a review of the latest developments.
Curr Opin Investig Drugs. 9: 1296-301, 2008.
51)  Madan RA, Xia Q, Chang VT, Oriscello RG, Kasimis B.
A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib.
Expert Opin Pharmacother. 8: 1425-31, 2007.
52)  Madan RA, Chang VT, Dever LL.
An uncommon presentation of HIV-related lymphoma.
AIDS Patient Care STDS. 21: 443-6, 2007.
53)  Arlen PM, Madan RA, Hodge JW, Schlom J, Gulley JL.
Combining Vaccines with Conventional Therapies for Cancer.
Update Cancer Ther. 2: 33-39, 2007.
54)  Gulley JL, Madan RA, Arlen PM.
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
Vaccine. 25 Suppl 2: B89-96, 2007.
55)  Madan RA, Arlen PM, Gulley JL.
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.
Expert Opin Biol Ther. 7: 543-54, 2007.
56)  Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J.
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Crit. Rev. Immunol. 27: 451-62, 2007.
57)  Madan RA, Lieberman R, Gulley JL, Dahut W, Arlen PM.
Significant prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent prostate cancer (AIPC) and a review of the literature.
Am J Ther. 14: 310-3, 2007.
58)  Madan RA, Arlen PM.
Abiraterone. Cougar Biotechnology.
IDrugs. 9: 49-55, 2006.
59)  Madan RA, Gulley JL, Arlen PM.
PSA-based vaccines for the treatment of prostate cancer.
Expert Rev Vaccines. 5: 199-209, 2006.
60)  Madan RA, Chang VT, Yook C, Baddoura FK, Srinivas S, Kasimis B.
Waldenstrom's macroglobulinemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature.
Leukemia. 18: 1433-5, 2004.
61)  Goldberg SL, Madan RA, Rowley SD, Pecora AL, Hsu JW, Tantravahi R.
Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
Blood. 101: 781, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 12/13/2013.